期刊文献+

2011版ATA/AACE《甲亢和其他病因甲状腺毒症诊治指南》解读 被引量:34

Management guidelines of hyperthyroidism and other causes of thyrotoxicosis issued by the American Thyroid Association and American Association of Clinical Endocrinologists
下载PDF
导出
摘要 美国甲状腺学会和临床内分泌医师学会在2011年6月联合发表新版《甲亢和其他病因甲状腺毒症诊治指南》。指南共提出100条建议,涵盖Graves病、毒性结节性甲状腺肿和毒性甲状腺腺瘤等疾病的病因学诊断和对症处理、131I、抗甲状腺药物和外科手术等治疗手段。另外,新指南还涉及到未成年甲亢、妊娠期甲亢、Graves眼病、亚临床甲亢和药物相关性甲状腺毒症等的诊治。本文解读指南中有关甲亢和其他病因甲状腺毒症的诊治建议。 The American Thyroid Association (ATA) and American Association of Clinical Endocrinologists (AACE) published Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American of Clinical Endocrinologists in June, 2011. The new guideline offers 100 proposals on the initial evaluation and management of Graves disease, toxic multi-nodular goiter or toxic adenoma including radioactive iodine, anti-thyroid drugs and surgery therapy. Besides, the guideline involves the diagnosis and treatment of Graves disease in children, adolescents or pregnant patients, Graves ophthalmopathy, subclinical hyperthyroidism and drug related hyperthyroidism. This review interprets the guideline about diagnosis and treatment of hyperthyroidism and other causes of the thyrotoxicosis.
出处 《世界临床药物》 CAS 2011年第9期564-570,共7页 World Clinical Drug
关键词 甲亢 甲状腺毒症 131I 抗甲状腺药物 甲状腺切除术 hyperthyroidism thyrotoxicosis ^131I anti-thyroid drugs thyroidectomy
  • 相关文献

参考文献24

  • 1Bahn Chair RS,Burch HB,Cooper DS,et al.Hyperthyroidism and other causes of thyrotoxicosis:management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists[J].Thyroid,2011,21(6):593-646.
  • 2George J.Kahaly,Luigi Bartalena,et al.The American Thyroid Association/American Association of Clinical Endocrinologists guidelines for hyperthyroidism and other causes of thyrotoxicosis:a European perspective[J].Thyroid,2011,21(6):585-591.
  • 3Yamashita S,Amino N,Shong YK.The American Thyroid Association and American Association of Clinical Endocrinologists hyperthyroidism and other causes of thyrotoxicosis guidelines:viewpoints from Japan and Korea[J].Thyroid,2011,21(6):577-580.
  • 4Cooper DS,Doherty GM,Haugen BR,et al.American Thyroid Association(ATA)Guidelines Taskforce on thyroid nodules and differentiated cancer[J].Thyroid,2009,19(11)1167-1214.
  • 5Trdisk F,Tallstedt L,Abraham-Nordling M,et al.Thyroidassociated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131[J].J Clin Endocrinol Metab,2009,94(10):3700-3707.
  • 6Peters H,Fischer C,Bogner U,et al.Radioiodine therapy of Graves' hyperthyroidism:standard vs.calculated 131 iodine activity.Results from aprospective,randomized,multicentre study[J].Eur J Clin Invest,1995,25(3):186-193.
  • 7Costaghola S,Morgenthaler NG,Hoermann R,et al.Second generation assay for thyrotropin receptor antibodies has superior diagnostics ensitivity for Graves' disease[J].J Clin Endocrinol Metab,1999,84(1):90-97.
  • 8Cooper DS.Antithyroid drugs[J].N Engl J Med,2005,352(9):905-917.
  • 9Klein I,Becker D,Levey GS.Treatment of hyperthyroid disease[J].AnnInt Med,1994,121(4):281-288.
  • 10Abraham P,Avenell A,Park CM,et al.A systematic review of drug therapy for Graves' hyperthyroidism[J].Eur J Endorinol,2005,153(4):489-498.

同被引文献270

引证文献34

二级引证文献175

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部